# US 2015/0147398 A1 · Paliperidone Implant Formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147398 A1
- Document ID: US20150147398A1
- Status: Published application
- Kind: A1
- Application number: 14/555,273
- Filed: 2014-11-26
- Published: 2015-05-28
- Earliest claimed: 2010-05-31
- Assignees: Laboratorios Farmaceuticos Rovi, S.A.
- Applicants: Laboratorios Farmacéuticos Rovi, S.A.
- Inventors: Ibon GUTIERRO ADURIZ; Guillermo FRANCO RODRÍGUEZ
- Web page: https://patentgrep.com/patent/US20150147398A1

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is paliperidone and/or its pharmaceutical acceptable salts in any combination thereof, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and DMSO as solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 8 weeks and wherein the composition has a pharmacokinetic profile in vivo suitable for the formulation to be administered each 8 weeks or even longer periods.

## Claims

### Claim 1

1) An injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is paliperidone and/or its pharmaceutical acceptable salts in any combination thereof, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 45:55 to 55:45 and DMSO as solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 8 weeks and wherein the composition has a pharmacokinetic profile in vivo suitable for the formulation to be administered each 8 weeks or longer periods, characterised in that the biocompatible copolymer has a molecular weight in the range of between 31 and 43 kDa and an inherent viscosity in the range of between 0.27-0.31 dl/g±10%.

### Claim 2 (depends on 1)

2) The composition of claim 1, wherein prior to administration the biocompatible copolymer is gamma or beta irradiated with a dose in the range of 10-30 kGy measured at a temperature between −40° C. and +35° C. to adjust its molecular weight to a range between 31 and 43 kDa and its inherent viscosity to a range of between 0.27-0.31 dl/g±10%.

### Claim 3 (depends on 1)

3) The composition claim 1, wherein the particle size distribution of the drug is less than 10% particles smaller than 10 microns; less than 10% particles larger than 225 microns, and a d0.5 value in the range of 40-90 microns.

### Claim 4 (depends on 1)

4) The composition according to claim 1, wherein the drug/(polymer+drug) mass ratio is about 33%.

### Claim 5 (depends on 1)

5) The composition according to claim 1, wherein the content of drug is about 13% w/w of total formulation and the viscosity of the solution comprising the polymer and the DMSO is in the range of 1.5-2.5. Pa·s.

### Claim 6

6) (canceled)

### Claim 7 (depends on 1)

7) A pharmaceutical kit suitable for the in situ formation of a biodegradable implant in a body comprising the composition of claim 1, wherein the drug and the biocompatible polymer are contained in a first container, and the solvent is contained in a second, separate container.

### Claim 8 (depends on 7)

8) The pharmaceutical kit according to claim 7, wherein at least one of the first and second containers is a syringe, a vial, a device or a cartridge, either disposable or not.

### Claim 9 (depends on 1)

9) A method for the manufacturing of a composition according to claim 1, the method comprising providing the biocompatible copolymer having an initial polymer weight higher than required for the intramuscular depot composition and then adjusting its molecular weight to between 31 and 43 kDa and its inherent viscosity to a range of 0.27-0.31 dl/g by irradiating it with gamma or beta radiation in the dose range of 10-30 kGy measured at a temperature between −40° C. and +35° C.

### Claim 10 (depends on 9)

10) The method according to claim 9 wherein the radiation dose irradiated to the polymer is in the range of 16-25 kGy measured at the temperature of 8° C.

### Claim 11 (depends on 9)

11) The method according to claim 9, wherein, a) when the biocompatible polymer has an initial molecular weight of about 50 kDa, it is irradiated with a radiation dose of about 16 kGy to reduce its molecular weight to between 27 and 47 kDa; b) when the biocompatible polymer has an initial molecular weight of about 54 kDa, it is irradiated with a radiation dose of about 25 kGy to reduce its molecular weight to between 31 and 43 kDa; or c) when the biocompatible polymer has an initial molecular weight of about 63 kDa, it is irradiated with a radiation dose of about 30 kGy to reduce its molecular weight to between 31 and 43 kDa.

### Claim 12

12) (canceled)

### Claim 13

13) (canceled)

### Claim 14

14) (canceled)

### Claim 15

15) (canceled)

### Claim 16

16) A method of administering paliperidone to a subject in need thereof, the method comprising:
a) administering intramuscularly doses of sustained release injectable depot composition comprising about 75 mg to about 250 mg of paliperidone at 24-day to 35-day intervals; and
b) administering intramuscularly doses of sustained release injectable depot composition comprising about 75 mg to about 250 mg of paliperidone at 48-day to 70-day intervals.

### Claim 17 (depends on 19)

17) The method of claim 19 comprising:
a) administering intramuscularly a dose of sustained release injectable depot composition comprising about 75 mg to about 250 mg of paliperidone;
b) after about 24 to about 35 days from the prior dose, administering intramuscularly a dose of sustained release injectable depot composition comprising about 75 mg to about 250 mg of paliperidone; and
c) after about 48 to about 70 days from the prior dose, administering intramuscularly a dose of sustained release injectable depot composition comprising about 75 mg to about 250 mg of paliperidone

### Claim 18

18) (canceled)

### Claim 19

19) A method of administering paliperidone to a subject in need thereof, the method comprising:
a) administering intramuscularly a dose of sustained release injectable depot composition comprising about 75 mg to about 250 mg of paliperidone; and
b) after about 48 to about 70 days from the prior dose, administering intramuscularly a dose of sustained release injectable depot composition comprising about 75 mg to about 250 mg of paliperidone.

### Claim 20

20) (canceled)

### Claim 21

21) A method of administering paliperidone to a subject in need thereof, the method comprising:
a) administering intramuscularly a dose of sustained release injectable depot composition comprising about 75 mg to about 250 mg of paliperidone;
b) after about 24 to about 35 days from the prior dose, administering intramuscularly a dose of sustained release injectable depot composition comprising about 75 mg to about 250 mg of paliperidone.

### Claim 22

22) (canceled)

### Claim 23

23) (canceled)

### Claim 24

24) (canceled)

### Claim 25

25) (canceled)

### Claim 26

26) (canceled)

### Claim 27 (depends on 16)

27) A method of treating a disease or disorder that is therapeutically responsive to risperidone or paliperidone, the method comprising:
a) administering paliperidone according to the method of claim 16.

### Claim 28 (depends on 17)

28) A method of treating a disease or disorder that is therapeutically responsive to risperidone or paliperidone, the method comprising:
a) administering paliperidone according to the method of claim 17.

### Claim 29

29) (canceled)

### Claim 30 (depends on 19)

30) A method of treating a disease or disorder that is therapeutically responsive to risperidone or paliperidone, the method comprising:
a) administering paliperidone according to the method of claim 19.

### Claim 31

31) (canceled)

### Claim 32 (depends on 21)

32) A method of treating a disease or disorder that is therapeutically responsive to risperidone or paliperidone, the method comprising:
a) administering paliperidone according to the method of claim 21.

### Claim 33

33) (canceled)

### Claim 34

34) (canceled)

### Claim 35

35) (canceled)

### Claim 36

36) (canceled)

### Claim 37

37) (canceled)

### Claim 38

38) (canceled)

### Claim 39

39) (canceled)

### Claim 40

40) (canceled)

### Claim 41

41) (canceled)

### Claim 42

42) (canceled)

### Claim 43

43) (canceled)

### Claim 44

44) (canceled)

### Claim 45

45) (canceled)

### Claim 46

46) (canceled)

### Claim 47

47) A sustained release injectable depot composition comprising: DMSO, paliperidone and/or its pharmaceutical acceptable salts in any combination thereof, and biocompatible poly(L-lactide)-co-(glycolide) (PLGA) copolymer having a lactic acid to glycolic acid monomer ratio ranging from 45:55 to 55:45, wherein:
the biocompatible copolymer has a molecular weight in the range of about 27 to about 47 kDa and an inherent viscosity in the range of about 0.27±10% to 0.31±10% dl/g; and
paliperidone has a particle size distribution described as follows: less than 10% of the total volume of particles being smaller than 10 microns; less than 10% of the total volume of particles being larger than 225 microns, and a d0.5 value in the range of 40-90 microns.

### Claim 48 (depends on 47)

48) The composition of claim 47, wherein, prior to administration, the biocompatible copolymer is irradiated with a dose in the range of about 10 to about 30 kGy of gamma- or beta-radiation measured at a temperature between −40° C. and +35° C.

### Claim 49 (depends on 47)

49) The composition of claim 47, wherein:
a) when the biocompatible polymer has an initial molecular weight of about 50 kDa, it is irradiated with a radiation dose of about 16 KGy measured at 8° C. to reduce its molecular weight to between about 27 and about 47 kDa, about 31 to about 43 kDa or about 31 to about 40 kDa;
b) when the biocompatible polymer has an initial molecular weight of about 54 kDa, it is irradiated with a radiation dose of about 25 kGy measured at 8° C. to reduce its molecular weight to between about 31 and about 43 kDa; or
c) when the biocompatible polymer has an initial molecular weight of about 63 kDa, it is irradiated with a radiation dose of about 30 kGy measured at 8° C. to reduce its molecular weight to between about 30 and about 43 kDa, or about 31 and about 36 kDa.

### Claim 50 (depends on 1)

50) The composition of claim 1, wherein:
a) the particle size distribution of paliperidone is described as follows: less than 10% of the total volume of particles being smaller than 10 microns; less than 10% of the total volume of particles being larger than 225 microns, and a d0.5 value in the range of 60-130 microns;
b) the mass ratio of drug to (polymer+drug) is in the range of about 25% to about 35%, expressed as the percentage of the drug weight with respect to total weight of the drug plus polymer;
c) the mass ratio of drug to final composition is in the range of about 10% to about 15% wt., expressed as the percentage of the weight of drug with respect the total weight of drug plus polymer plus solvent;
d) the mass ratio of solvent to drug is in the range of about 12:1 to about 4:1;
e) the mass ratio of polymer to polymeric solution, expressed as the weight percentage of polymer with respect to the weight of polymer+solvent, is about 25-35% wt or about 30-40% wt;
f) the mass ratio of solvent to polymeric solution expressed as the weight percentage of solvent with respect to the weight of polymer plus solvent, is about 60% to about 80% wt; and/or
g) the mass ratio of polymer to injectable composition, expressed as the weight percentage of polymer with respect to the weight of polymer plus solvent plus drug, is about 24% to about 34% wt.

### Claim 51

51) (canceled)

### Claim 52

52) (canceled)

### Claim 53

53) (canceled)

### Claim 54

54) (canceled)

### Claim 55

55) (canceled)

### Claim 56

56) (canceled)

### Claim 57

57) (canceled)

### Claim 58

58) (canceled)

### Claim 59

59) (canceled)

### Claim 60

60) (canceled)

### Claim 61

61) (canceled)

### Claim 62

62) (canceled)

### Claim 63

63) (canceled)

### Claim 64 (depends on 1)

64) The composition of claim 1, wherein the injectable composition releases no more than 20% wt. of its charge of paliperidone within 24 hours after being placed in an aqueous environment.

### Claim 65 (depends on 64)

65) The composition of claim 64, wherein the injectable composition releases at least 0.1% wt of its charge of drug within 24 hours after being placed in an aqueous environment.

### Claim 66

66) (canceled)

### Claim 67

67) (canceled)

### Claim 68 (depends on 1)

68) The composition of claim 1, wherein >0% to up to about 20% wt. of the drug is dissolved in the DMSO or polymeric solution to form the injectable composition.

### Claim 69 (depends on 1)

69) The composition of claim 1, wherein:
the particle size distribution of paliperidone is described as follows: less than 10% of the total volume of particles being smaller than 10 microns; less than 10% of the total volume of particles being larger than 225 microns, and a d0.5 value in the range of 40-90 microns;
the mass ratio of drug to (polymer+drug) is in the range of about 25% to about 35%;
the mass ratio of drug to final composition is in the range of about 10% to about 15% wt., expressed as the percentage of the weight of drug with respect the total weight of drug plus polymer plus solvent;
the mass ratio of solvent to drug is in the range of about 10:1 to about 4:1;
the mass ratio of polymer to polymeric solution, expressed as the weight percentage of polymer with respect to the weight of polymer+solvent, is about 25-35% wt;
the mass ratio of solvent to polymeric solution, expressed as the weight percentage of solvent with respect to the weight of polymer plus solvent, is about 60% to about 80% wt;
the mass ratio of polymer to injectable composition, expressed as the weight percentage of polymer with respect to the weight of polymer plus solvent plus drug, is about 24% to about 34% wt; and
>0% to up to about 20% wt. of the drug is dissolved in the DMSO or polymeric solution to form the injectable composition.

### Claim 70 (depends on 1)

70) The composition of claim 1, wherein:
the particle size distribution of paliperidone is described as follows: less than 10% of the total volume of particles being smaller than 10 microns; less than 10% of the total volume of particles being larger than 225 microns, and a d0.5 value in the range of 40-90 microns;
the mass ratio of drug to (polymer+drug) is in the range of about 32% to about 34%;
the mass ratio of drug to final composition is in the range of about 12% to about 14% wt., expressed as the percentage of the weight of drug with respect the total weight of drug plus polymer plus solvent;
the mass ratio of solvent to drug is in the range of about 5:1 to about 4:1;
the mass ratio of polymer to polymeric solution, expressed as the weight percentage of polymer with respect to the weight of polymer+solvent, is about 28 to about 32% wt;
the mass ratio of solvent to polymeric solution, expressed as the weight percentage of solvent with respect to the weight of polymer plus solvent, is about 67% to about 72% wt;
the mass ratio of polymer to injectable composition, expressed as the weight percentage of polymer with respect to the weight of polymer plus solvent plus drug, is about 25% to about 27% wt; and
>0% to up to about 20% wt. of the drug is dissolved in the DMSO or polymeric solution to form the injectable composition.

### Claim 71 (depends on 1)

71) The composition of claim 1, wherein the injectable composition is prepared by:
a) mixing the DMSO and the PLGA copolymer to form a polymeric solution; and
b) mixing the paliperidone and the polymeric solution to form the injectable composition.
